We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.15%
2 Technology 17.4%
3 Communication Services 12.66%
4 Financials 12.19%
5 Industrials 5.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBTYK icon
26
Liberty Global Class C
LBTYK
$3.51B
$197M 1.16%
6,991,640
+1,468,984
+27% +$39.7M
LBTYA icon
27
Liberty Global Class A
LBTYA
$3.61B
$192M 1.13%
6,629,602
+1,302,109
+24% +$36.3M
VRSK icon
28
Verisk Analytics
VRSK
$24.6B
$172M 1.01%
1,424,553
-397,149
-22% -$46.2M
BPYU
29
DELISTED
Brookfield Property REIT Inc. Class A Common Stock
BPYU
$169M 1%
+8,054,215
New +$162M
NXPI icon
30
NXP Semiconductors
NXPI
$58.3B
$141M 0.83%
1,650,000
-1,023,802
-38% -$98.2M
AZN icon
31
AstraZeneca
AZN
$250B
$135M 0.8%
1,710,000
-215,000
-11% -$16.3M
EFX icon
32
Equifax
EFX
$20.8B
$107M 0.63%
815,817
-23,142
-3% -$3.01M
XLRN
33
DELISTED
Acceleron Pharma
XLRN
$105M 0.62%
1,840,732
+439,732
+31% +$21.6M
ASND icon
34
Ascendis Pharma A/S
ASND
$16B
$103M 0.61%
1,457,297
– –
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$99.8M 0.59%
1,531,278
+50,000
+3% +$2.94M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$89.1M 0.53%
1,795,500
+100,000
+6% +$5.09M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
$88.3M 0.52%
625,000
– –
KYNB
38
Kyntra Bio
KYNB
$28.3M
$84.7M 0.5%
55,800
-12,900
-19% -$19.9M
SINA
39
DELISTED
Sina Corp
SINA
$78.1M 0.46%
1,124,224
+489,224
+77% +$36.6M
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$77.9M 0.46%
5,125,000
+475,000
+10% +$7.28M
AVA icon
41
Avista
AVA
$3.25B
$74.3M 0.44%
1,470,000
+358,277
+32% +$18.3M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$384M
$74.1M 0.44%
867,500
-207,500
-19% -$20.8M
NVCR icon
43
NovoCure
NVCR
$1.87B
$70.7M 0.42%
1,350,000
-240,000
-15% -$9.55M
TFCFA
44
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$66.5M 0.39%
1,435,000
+200,000
+16% +$9.16M
BABA icon
45
Alibaba
BABA
$308B
$61.5M 0.36%
+373,000
New +$66M
CA
46
DELISTED
CA, Inc.
CA
$61M 0.36%
+1,382,361
New +$59.6M
RETA
47
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$55.1M 0.33%
+673,500
New +$47.5M
AMRN
48
Amarin Corp
AMRN
$302M
$53.9M 0.32%
165,635
-58,615
-26% -$4.43M
IOVA icon
49
Iovance Biotherapeutics
IOVA
$1.94B
$53.2M 0.31%
4,725,000
+300,000
+7% +$4.26M
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
$52.1M 0.31%
1,370,000
+185,000
+16% +$8.19M
1
2
3 4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Farallon Capital Management held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Farallon Capital Management's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Communication Services.

  • Farallon Capital Management's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Farallon Capital Management added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Farallon Capital Management's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Farallon Capital Management fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Farallon Capital Management's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Farallon Capital Management opened 26 new positions and closed 20 in Q3 2018.
  • Farallon Capital Management's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.